JPS60136512A - 脂質代謝改善剤 - Google Patents

脂質代謝改善剤

Info

Publication number: JPS60136512A
Authority: JP; Japan
Prior art keywords: dolichol; preventive; remedy; oil; active component
Prior art date: 1983-12-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP58244229A

Other languages

English (en)

Japanese (ja)

Other versions

JPH0455168B2 (2

Inventor

Isao Yamatsu

功山津

Takeshi Suzuki

鈴木　赳

Shinya Abe

信也阿部

Koji Nakamoto

中本　浩司

Shoji Kajiwara

彰治梶原

Koichi Katayama

片山　幸一

So Tsunoda

角田　創

Manabu Murakami

学村上

Hideki Ono

英樹小野

Koji Yamada

浩司山田

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eisai Co Ltd

Original Assignee

Eisai Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-12-26

Filing date

1983-12-26

Publication date

1985-07-20

1983-12-26 Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd

1983-12-26 Priority to JP58244229A priority Critical patent/JPS60136512A/ja

1984-12-21 Priority to US06/684,875 priority patent/US4613593A/en

1984-12-27 Priority to EP84116353A priority patent/EP0149847A3/en

1985-07-20 Publication of JPS60136512A publication Critical patent/JPS60136512A/ja

1992-09-02 Publication of JPH0455168B2 publication Critical patent/JPH0455168B2/ja

Status Granted legal-status Critical Current

Links

230000003449 preventive effect Effects 0.000 title abstract description 4
201000005577 familial hyperlipidemia Diseases 0.000 title abstract 2
150000002031 dolichols Chemical class 0.000 claims abstract description 27
239000003795 chemical substances by application Substances 0.000 claims abstract description 14
-1 dolichol phosphate Chemical class 0.000 claims abstract description 11
229910019142 PO4 Inorganic materials 0.000 claims abstract description 5
239000010452 phosphate Substances 0.000 claims abstract description 5
206010003210 Arteriosclerosis Diseases 0.000 claims abstract description 4
208000011775 arteriosclerosis disease Diseases 0.000 claims abstract description 4
208000031226 Hyperlipidaemia Diseases 0.000 claims description 7
230000002265 prevention Effects 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 4
150000002148 esters Chemical class 0.000 claims description 4
230000037356 lipid metabolism Effects 0.000 claims description 4
239000002253 acid Substances 0.000 claims 2
239000004615 ingredient Substances 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract description 10
239000000203 mixture Substances 0.000 abstract description 7
239000008187 granular material Substances 0.000 abstract description 5
210000004185 liver Anatomy 0.000 abstract description 4
239000000843 powder Substances 0.000 abstract description 4
239000002775 capsule Substances 0.000 abstract description 3
BDMCAOBQLHJGBE-UHFFFAOYSA-N C60-polyprenol Natural products CC(=CCCC(=CCCC(=CCCC(=CCCC(=C/CCC(=C/CCC(=C/CCC(=C/CCC(=C/CCC(=C/CCC(=C/CCC(=C/CO)C)C)C)C)C)C)C)C)C)C)C)C BDMCAOBQLHJGBE-UHFFFAOYSA-N 0.000 abstract description 2
229930186185 Polyprenol Natural products 0.000 abstract description 2
229920001731 Polyprenol Polymers 0.000 abstract description 2
240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 2
238000000855 fermentation Methods 0.000 abstract description 2
230000004151 fermentation Effects 0.000 abstract description 2
244000005700 microbiome Species 0.000 abstract description 2
150000003096 polyprenols Chemical class 0.000 abstract description 2
239000003826 tablet Substances 0.000 abstract description 2
239000003921 oil Substances 0.000 description 16
239000010410 layer Substances 0.000 description 11
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
238000004519 manufacturing process Methods 0.000 description 10
241000700159 Rattus Species 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
238000000034 method Methods 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical class [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
235000013372 meat Nutrition 0.000 description 4
238000003756 stirring Methods 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
238000001816 cooling Methods 0.000 description 3
239000003814 drug Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000000605 extraction Methods 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
210000000496 pancreas Anatomy 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
241000205585 Aquilegia canadensis Species 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
108010019160 Pancreatin Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
GYBNOAFGEKAZTA-QOLULZROSA-N [(6z,10e,14e)-3,7,11,15,19-pentamethylicosa-6,10,14,18-tetraenyl] dihydrogen phosphate Chemical compound OP(=O)(O)OCCC(C)CC\C=C(\C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C GYBNOAFGEKAZTA-QOLULZROSA-N 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
210000000709 aorta Anatomy 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000003086 colorant Substances 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
229940055695 pancreatin Drugs 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
230000009278 visceral effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
101710186630 Insulin-1 Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
102100027441 Nucleobindin-2 Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
235000009470 Theobroma cacao Nutrition 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
159000000032 aromatic acids Chemical class 0.000 description 1
UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
239000001354 calcium citrate Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
239000010639 cypress oil Substances 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
239000012156 elution solvent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
239000003925 fat Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000001341 hydroxy propyl starch Substances 0.000 description 1
235000013828 hydroxypropyl starch Nutrition 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920001289 polyvinyl ether Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
235000015277 pork Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000011121 sodium hydroxide Nutrition 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
235000013337 tricalcium citrate Nutrition 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP58244229A 1983-12-26 1983-12-26 脂質代謝改善剤 Granted JPS60136512A (ja)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
JP58244229A JPS60136512A (ja)	1983-12-26	1983-12-26	脂質代謝改善剤
US06/684,875 US4613593A (en)	1983-12-26	1984-12-21	Therapeutic and preventive agent containing dolichol
EP84116353A EP0149847A3 (en)	1983-12-26	1984-12-27	Therapeutic and preventive agent containing dolichol

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP58244229A JPS60136512A (ja)	1983-12-26	1983-12-26	脂質代謝改善剤

Publications (2)

Publication Number	Publication Date
JPS60136512A true JPS60136512A (ja)	1985-07-20
JPH0455168B2 JPH0455168B2 (2)	1992-09-02

Family

ID=17115658

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP58244229A Granted JPS60136512A (ja)	1983-12-26	1983-12-26	脂質代謝改善剤

Country Status (2)

Country	Link
US (1)	US4613593A (2)
JP (1)	JPS60136512A (2)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA01009893A (es)	1999-04-01	2003-07-28	Esperion Therapeutics Inc	Compuestos con eter, composiciones y usos de estos.
US6525035B1 (en) *	1999-06-10	2003-02-25	Sass & Sass, Inc.	Therapeutic composition and methods
US7304093B2 (en) *	2000-10-11	2007-12-04	Esperion Therapeutics, Inc.	Ketone compounds and compositions for cholesterol management and related uses
AU2002211666A1 (en)	2000-10-11	2002-04-22	Esperion Therapeutics, Inc.	Sulfide and disulfide compounds and compositions for cholesterol management and related uses
WO2002030860A2 (en)	2000-10-11	2002-04-18	Esperion Therapeutics, Inc.	Ketone compounds and compositions for cholesterol management and related uses
MXPA03003024A (es)	2000-10-11	2003-07-14	Esperion Therapeutics Inc	Compuestos de sulfoxido y bis-sulfoxido y composiciones para el control de colesterol y usos relacionados.
IL155215A0 (en)	2000-10-11	2003-11-23	Esperion Therapeutics Inc	Ether compounds and compositions for cholesterol management and related uses
US20040122091A1 (en) *	2000-10-11	2004-06-24	Esperion Therapeutics, Inc.	Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US20040192771A1 (en) *	2001-10-11	2004-09-30	Dasseux Jean-Louis Henri	Ether compounds and compositions for cholesterol management and related uses
US20040204502A1 (en) *	2001-10-11	2004-10-14	Dasseux Jean-Louis Henri	Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US20050020694A1 (en) *	2001-10-11	2005-01-27	Dasseux Jean-Louis Henri	Sulfide and disulfide compounds and compositions for cholesterol management and related uses
US20030236212A1 (en) *	2002-04-10	2003-12-25	Jean-Louis Dasseux	Functionalized long chain derivatives as acyl coenzyme-A mimics, compositions thereof, and methods of cholesterol management and related uses
MXPA05000050A (es) *	2002-07-03	2005-04-08	Esperion Therapeutics Inc	Composiciones farmaceuticas y metodos para tratar, prevenir y manejar el colesterol, dislipidemia y enfermedades relacionadas.
US20040048910A1 (en) *	2002-08-22	2004-03-11	Bove Susan Elizabeth	Method of treating osteoarthritis
HUE036646T2 (hu) *	2003-01-23	2018-07-30	Esperion Therapeutics Inc	Hidroxilvegyületek és kompozícióik koleszterin szabályozására és kapcsolódó alkalmazásokra
ATE428411T1 (de) *	2003-11-07	2009-05-15	Jj Pharma Inc	Hdl-verstärkende kombinationstherapie-komplexe
US20050192347A1 (en) *	2003-12-23	2005-09-01	Dasseux Jean-Louis H.	Urea and thiourea compounds and compositions for cholesterol management and related uses
JP2007525408A (ja) *	2003-12-24	2007-09-06	エスペリオンセラピューティクス，インコーポレイテッド	コレステロール管理および関連使用のためのケトン化合物および組成物
RU2006146479A (ru) *	2004-06-09	2008-07-20	Аванир Фармасьютикалс (Us)	Небольшие молекулярные медиаторы для лечения гиперхолестеринемии и связанных заболеваний
MXJL06000069A (es) *	2004-06-09	2007-04-10	Avanir Pharmaceuticals	Derivados heterociclicos para el tratamiento de hiperlipidemia y enfermedades relacionadas.
EP1753782A1 (en) *	2004-06-09	2007-02-21	Avanir Pharmaceuticals	Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
WO2006045010A2 (en) *	2004-10-20	2006-04-27	Resverlogix Corp.	Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
CA2617213C (en) *	2005-07-29	2014-01-28	Resverlogix Corp.	Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
WO2008092231A1 (en)	2007-02-01	2008-08-07	Resverlogix Corp.	Compounds for the prevention and treatment of cardiovascular diseases
EP2167069B1 (en)	2007-05-23	2011-10-26	Amcol International Corporation	Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
KR101629356B1 (ko)	2008-06-26	2016-06-13	리스버로직스 코퍼레이션	퀴나졸리논 유도체의 제조방법
AU2010204106B2 (en)	2009-01-08	2014-05-08	Resverlogix Corp.	Compounds for the prevention and treatment of cardiovascular disease
NZ755378A (en)	2009-03-18	2022-07-29	Resverlogix Corp	Novel quinazolinones and related compounds for use as anti-inflammatory agents
KR20190091564A (ko)	2009-04-22	2019-08-06	리스버로직스 코퍼레이션	신규한 소염제
PE20161551A1 (es)	2009-09-03	2017-01-18	Pfizer Vaccines Llc	Vacuna de pcsk9
RU2425669C1 (ru) *	2010-04-13	2011-08-10	Общество С Ограниченной Ответственностью "Гамаветфарм"	Средство для профилактики и лечения острого и хронического панкреатита
RU2427284C1 (ru) *	2010-06-29	2011-08-27	Общество С Ограниченной Ответственностью "Гамаветфарм"	Биологически активная добавка и способ ее получения
US20140004142A1 (en)	2011-03-02	2014-01-02	Pfizer Inc.	Pcsk9 vaccine
RU2640115C2 (ru)	2011-11-01	2017-12-26	Ресверлоджикс Корп.	Фармацевтические композиции замещенных хиназолинонов
US9073878B2 (en)	2012-11-21	2015-07-07	Zenith Epigenetics Corp.	Cyclic amines as bromodomain inhibitors
US9765039B2 (en)	2012-11-21	2017-09-19	Zenith Epigenetics Ltd.	Biaryl derivatives as bromodomain inhibitors
AU2013365926B9 (en)	2012-12-21	2019-01-17	Zenith Epigenetics Ltd.	Novel heterocyclic compounds as bromodomain inhibitors
WO2014138586A1 (en) *	2013-03-08	2014-09-12	Duke University	Compositions and methods for the diagnosis and treatment of dolichol deficiency related disorders
US9076336B2 (en)	2013-03-15	2015-07-07	Volkswagen Ag	Personalized parking assistant
WO2015123291A1 (en)	2014-02-11	2015-08-20	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Pcsk9 vaccine and methods of using the same
JO3789B1 (ar)	2015-03-13	2021-01-31	Resverlogix Corp	التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
RU2022102472A (ru)	2015-03-13	2022-03-15	Эсперион Терапеутикс, Инк.	Фиксированные комбинации и составы, содержащие etc-1002 и эзетимиб, и способы лечения или уменьшения риска развития сердечно-сосудистого заболевания
MA41793A (fr)	2015-03-16	2018-01-23	Esperion Therapeutics Inc	Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
RU2605264C1 (ru) *	2015-12-02	2016-12-20	Общество С Ограниченной Ответственностью "Гамаветфарм"	Средство для растворения желчных камней и лечения желчнокаменной болезни
CN112437766A (zh)	2019-06-21	2021-03-02	艾斯柏伦治疗公司	制备贝派地酸及其组合物的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4175139A (en) *	1977-08-10	1979-11-20	Eisai Co. Ltd.	Hypertension treating agent containing polyprenyl alcohol
JPS6058209B2 (ja) *	1978-12-01	1985-12-19	エーザイ株式会社	β，γ−ジヒドロポリプレニルアルコ−ルおよびそれからなる血圧降下剤

1983
- 1983-12-26 JP JP58244229A patent/JPS60136512A/ja active Granted
1984
- 1984-12-21 US US06/684,875 patent/US4613593A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US4613593A (en)	1986-09-23
JPH0455168B2 (2)	1992-09-02

Publication	Publication Date	Title
JPS60136512A (ja)	1985-07-20	脂質代謝改善剤
KR20000052687A (ko)	2000-08-25	마그네슘 (-)히드록시시트레이트, 그의 제조 방법, 용도 및 그를함유하는 특정 제약 조성물
JPH07300412A (ja)	1995-11-14	活性酸素消去剤及びこれを含む組成物
JP2003286167A (ja)	2003-10-07	エピガロカテキンガレートを含有するアセチルコリンエステラーゼ阻害剤、薬学的製剤及び食品
JPH0133082B2 (2)	1989-07-11
JPH07223940A (ja)	1995-08-22	活性酸素消去剤及びこれを含有する組成物
DE3031788C2 (2)	1988-03-31
JPS61143377A (ja)	1986-07-01	シリビニン誘導体、その製法及びこれを含有する火傷、肝臓障害及びキノコ毒の治療剤
JPH07300422A (ja)	1995-11-14	活性酸素消去剤及びこれを含む組成物
US4791105A (en)	1988-12-13	Therapeutic and preventive agent containing dolichol
US4603126A (en)	1986-07-29	Therapeutic and preventive agent containing dolichol
EP0149847A2 (en)	1985-07-31	Therapeutic and preventive agent containing dolichol
US3143469A (en)	1964-08-04	Anti-cholesterol nicotinic acid nu-oxide
US4599328A (en)	1986-07-08	Therapeutic and preventive agent containing dolichol
JP3142192B2 (ja)	2001-03-07	血中脂質改善剤及びこれを含有する組成物
JPH0753393A (ja)	1995-02-28	動脈硬化抑制剤及びこれを含む食品又は医薬
KR100198490B1 (ko)	1999-06-15	간장질환 치료용 의약 조성물
JP3178763B2 (ja)	2001-06-25	シムノールサルフェート製造法
US3155579A (en)	1964-11-03	Therapeutic composition for the treatment of disturbances of the water metabolism characterized by an insufficient elmination of water
JP3495085B2 (ja)	2004-02-09	活性酸素消去剤及びこれを含む組成物
JPS63156723A (ja)	1988-06-29	骨粗鬆症治療剤
US3482016A (en)	1969-12-02	Method for treating fascioliasis
KR102069125B1 (ko)	2020-01-22	강황 추출물을 포함하는 간손상 예방 및 치료용 약학 조성물
US1166208A (en)	1915-12-28	Physiologically-active base.
US4894393A (en)	1990-01-16	Dithiocarbamate-choline adduts and use thereof in treatment of brain diseases